Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPci-pal Regulatory News (PCIP)

Share Price Information for Pci-pal (PCIP)

Share Price is delayed by 15 minutes
Get Live Data
49.00    0.00 (0.00%)
Bid:
48.00
Ask:
50.00
Spread: 2.00 (4.167%)
Market Cap: £35.50m
PCIP Live PriceLast checked at - London Stock Exchange

Intraday Pci-pal Share Chart

HIPAA, HITRUST & SOC 2 Type II certification

14 Apr 2026 07:00

RNS Number : 2462A
PCI-PAL PLC
14 April 2026
 

 

 

Reach - Non-Regulatory Announcement

 

14 April 2026

 

PCI-PAL PLC

("PCI Pal", "the Group", or the "Company")

 

Achievement of HIPAA, HITRUST, and SOC 2 Type II certification

 

PCI-PAL PLC (AIM: PCIP), the global cloud provider of secure payment solutions for business communications, is pleased to announce that it has successfully achieved HIPAA, HITRUST and SOC 2 Type II compliance, enhancing its ability to support enterprise customers operating in highly regulated environments, particularly in the United States.

 

HIPAA (Health Insurance Portability and Accountability Act) is the key US healthcare data protection regulation, imposing strict security and privacy requirements on organisations handling sensitive patient information across the healthcare industry.

 

HITRUST is a leading certifiable security framework in the US healthcare sector, providing a comprehensive and auditable approach to managing data protection, privacy and regulatory compliance, and is often used to demonstrate alignment with HIPAA requirements.

 

SOC 2 Type II is a widely recognised and adopted independent audit standard in the US, validating that strong security and data protection controls are operating effectively over time, and is commonly expected by enterprise customers in the US.

 

Combined these achievements are exceptional in the Company's industry and reflect PCI Pal's continued commitment to maintaining the highest levels of data security, privacy, and regulatory compliance for not only its customers, but also in supporting its partners many of whom operate extensively across the US enterprise space.

 

Commenting, James Barham, Chief Executive Officer of PCI Pal, said:

 

"Achieving HIPAA and HITRUST audited compliance, alongside our successful SOC 2 Type II attestation, is an important milestone for PCI Pal. It underscores our continued investment in robust and regulated security frameworks, which is supporting enhanced competitive differentiation and positioning for the Company, as well as building additional customer trust. Together, they provide our customers with independently validated assurance in our ability to meet rigorous compliance requirements while delivering secure, reliable, enterprise-grade cloud solutions.

 

"For our partners, these achievements further strengthen an already comprehensive compliance and security foundation across the PCI Pal cloud platform. They also reinforce the basis for mutual growth across both human and AI engagement environments, as we continue to deliver incremental value and deepen strategic relationships.

 

"With expansion across enterprise customers in the US a key strategic goal, these standards further enhance our ability to engage with large, regulated organisations and position PCI Pal to capitalise on its significant market opportunity at pace."

 

 

For further information, please contact:

 

PCI-PAL PLC

Via Walbrook PR

James Barham - Chief Executive Officer

Ryan Murray - Chief Financial Officer

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

+44 (0) 20 7227 0500

Marc Milmo/ Fergus Sullivan (Corporate Finance)

Sunila De Silva (Corporate Broking)

 

Walbrook PR

+44 (0) 20 7933 8780

Tom Cooper/Nick Rome

+44 (0) 797 122 1972

tom.cooper@walbrookpr.com

 

 

About PCI Pal:

 

PCI Pal is a leading provider of secure, cloud-based payment and data protection solutions that enable organisations to take frictionless, compliant payments seamlessly integrated to any business communications environment including voice, chat, messaging, social media, and email. PCI Pal's platform supports all forms of customer engagement, whether human-to-human or AI-driven conversations.

 

PCI Pal has an extensive partner eco-system with its products resold by many of the world's leading Communications, CCaaS, and UCaaS vendors. Its platform integrates with a broad range of digital payment methods and connects to the majority of leading payment service providers globally.

 

For more information visit www.pcipal.com or follow the team on LinkedIn: https://www.linkedin.com/company/pci-pal/

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAXXLFFQZLBBBF
Date   Source Headline
28th Jun 20241:15 pmRNSIssue of Equity & Total Voting Rights
27th Jun 20247:00 amRNSSettlement of UK and US Patent Litigation
5th Jun 20243:02 pmRNSIssue of Equity & TVR
4th Jun 20241:40 pmRNSFurther details following successful COA hearing
22nd May 20247:00 amRNSVictory for PCI Pal in Court of Appeal
17th Apr 20245:45 pmRNSHolding(s) in Company
8th Apr 202410:28 amRNSIssue of Equity & TVR
5th Apr 20247:00 amRNSIssue of Options & Director Share Purchases
4th Apr 202410:24 amRNSIssue of Equity & TVR
28th Mar 20246:15 pmRNSHolding(s) in Company
27th Mar 20247:00 amRNSExercise of Options, Director/PCA Dealings & TVR
26th Mar 202410:57 amRNSPDMR Issue of Options
12th Mar 202412:55 pmRNSResult of Oversubscribed Placing & TVR
12th Mar 20247:00 amRNSProposed Placing to raise up to £3.5m
27th Feb 20247:00 amRNSInterim Results, Board Change & Presentations
20th Feb 20247:00 amRNSNotice of Results, Analyst & Investor Presentation
6th Feb 20247:00 amRNSTrading Update & Notice of Results
26th Jan 202412:50 pmRNSUK Patent Case Update
22nd Jan 20244:59 pmRNSHolding(s) in Company
15th Jan 202412:20 pmRNSIssue of Equity
20th Dec 20237:00 amRNSSuccessful Completion of Form of Order Hearing
19th Dec 20237:00 amRNSUK Court Hearing
12th Dec 20231:40 pmRNSResult of AGM
12th Dec 20237:00 amRNSAGM Statement
24th Nov 202310:45 amRNSAnnual Financial Report & Notice of AGM
13th Nov 20237:00 amRNSNew strategic reseller partnership with Zoom
9th Nov 20237:00 amRNSFinal Results, Analyst Briefing & Investor Pres
6th Nov 20237:00 amRNSNotice of Results Analyst Briefing & Investor Pres
5th Oct 202311:49 amRNSIssue of Equity
4th Oct 20235:13 pmRNSHolding(s) in Company
3rd Oct 20237:00 amRNSDetail on Patent Case Outcome & Trading Update
25th Sep 20235:29 pmRNSTotal Victory for PCI Pal in UK High Court
4th Sep 20237:00 amRNSHolding(s) in Company
26th Jun 202311:33 amRNSHolding(s) in Company
7th Jun 20237:00 amRNSBreach of confidentiality agreement by Sycurio Ltd
30th May 20237:00 amRNSDirector/PDMR Share Purchase
25th May 202311:08 amRNSDirector/PDMR Share Purchase
24th May 20237:00 amRNSTrading and Patent Case Updates
14th Mar 20237:00 amRNSInterim Results, Analyst Briefing & Investor Pres
13th Mar 20237:49 amRNSSVB Update
28th Feb 20237:00 amRNSNotice of Results, Analyst Call & Investor Pres
2nd Feb 20237:00 amRNSTrading Update & Notice of Results
27th Oct 202212:32 pmRNSResult of AGM
27th Oct 20227:00 amRNSAGM Statement
20th Oct 20227:00 amRNSPDMR Shareholding
7th Oct 20227:00 amRNSDirector/PDMR Issue of Options
6th Oct 20223:13 pmRNSDirector/PDMR share purchase
4th Oct 202210:37 amRNSAnnual Financial Report & Notice of AGM
22nd Sep 20227:00 amRNSPCI Pal launches open banking payments product
6th Sep 20227:00 amRNSFinal Results, Analyst Briefing & Investor Pres

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.